Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax™ ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix™-HepB/Hib-MenAC

Trial Profile

Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax™ ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix™-HepB/Hib-MenAC

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Hib-DTP-hepatitis B-meningococcal vaccine groups A and C conjugate (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top